Articles

Perspective

Published on 01 August 2012

Health professionals in the risk communication process on counterfeit medicines

Abstract:ย  Communication is a key component in the fight against counterfeit medicines affecting the lives of patients. Two types of risk communication should be distinguished: pro-active and reactive. Reactive communication...

Author(s): Luc Besanรงon

counterfeit medicines, healthcare professionals, risk communication

DOI: 10.5639/gabij.2012.0103-4.026

14.855 views

Read more โ†’

Perspective

Published on 03 July 2012

Terminology for biosimilarsโ€“a confusing minefield

Author byline as per print journal:ย Robin Thorpe, PhD, FRCPath;ย Meenu Wadhwa, PhD Abstract:ย  Biosimilars are firmly established in the EU as copy biologicals with a clear and effective regulatory route for...

Author(s): Meenu Wadhwa, PhD, Robin Thorpe, PhD, FRCPath

comparability, guidelines, non-innovator biologic, quality, safety

DOI: 10.5639/gabij.2012.0103-4.023

31.525 views

Read more โ†’

Review Article

Published on 02 July 2012

Reference pricing systems in Europe: characteristics and consequences

Author byline as per print journal:ย Pieter Dylst, PharmD;ย Professor Steven Simoens, MSc, PhD;ย Professor Arnold G Vulto, PharmD, PhD Introduction:ย A reference pricing system is a system that establishes a common reimbursement level...

Author(s): Pieter Dylst, PharmD, Professor Arnold G Vulto, PharmD, PhD, FCP, Steven Simoens, MSc, PhD

Europe, generic drugs, reference pricing system, reimbursement, review

DOI: 10.5639/gabij.2012.0103-4.028

89.659 views

Read more โ†’

Original Research

Published on 02 July 2012

Saving money in the European healthcare systems with biosimilars

Introduction:ย The use of biotechnological manufactured drugs, or biologicals, has increased massively over the past few years. Used especially in the treatment of cancer and other severe diseases, biologicals incur high...

Author(s): Robert Haustein, Christoph de Millas, Ariane Hรถer, MD, Professor Bertram Hรคussler, MD

biologicals, biosimilars, cost savings, costs, epo, Europe, G-CSF, MAB

DOI: 10.5639/gabij.2012.0103-4.036

44.262 views

Read more โ†’

Commentary

Published on 02 July 2012

Pharmacovigilance of biosimilars: challenges and possible solutions

Author byline as per print journal:ย Thijs J Giezen, PharmD, PhD;ย Sabine MJM Straus, MD, PhD Abstract:ย  Post-marketing surveillance is essential to detect, assess and prevent adverse reactions of chemically synthesized small...

Author(s): Sabine MJM Straus, MD, PhD, Thijs J Giezen, PharmD, PhD, MSc

biologicals, biosimilars, immunogenicity, pharmacovigilance, traceability

DOI: 10.5639/gabij.2012.0103-4.033

16.780 views

Read more โ†’

Editorial

Published on 02 August 2012

Generics policiesโ€“a globally-relevant implementation challenge

Abstract:ย  Vogler and Zimmerman, reporting on the 2011 Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference, have noted the incomplete application of generics policies in many settings, and have called for...

Author(s): Andy Gray, MScPharm, FPS, FFIP

generics policies, transparency, WHO policy

DOI: 10.5639/gabij.2012.0103-4.027

26.455 views

Read more โ†’

Letters to the Editor

Published on 11 October 2012

A clinician’s view of the ethics of the use of biosimilars

Abstract:ย  Comment on theย Letters to the Editorย by Dr Carlo Petrini: A bioethicistโ€™s view of the use of biosimilars Submitted: 8 October 2012; Revised: 9 October 2012; Accepted: 9 October 2012;...

Author(s): Dr Kalle Hoppu

DOI: 10.5639/gabij.2012.0103-4.035

9.242 views

Read more โ†’

Letters to the Editor

Published on 11 October 2012

A bioethicist’s view of the use of biosimilars

Abstract:ย  In recognition of the many ethically sensitive issues raised by the production and use of biosimilar medicinal products, the author imagines having to answer the non-multiple choice question โ€˜From...

Author(s): Carlo Petrini, PhD

bioethics, drugs, ethics committees, legislation, risk, safety

DOI: 10.5639/gabij.2012.0103-4.034

12.281 views

Read more โ†’

Editor's Letter

Published on 14 November 2012

Latest features in GaBI Journal, 2012, issue 3-4

This issue of the GaBI Journal uses a number of article formats to cover a range of issues related to generics and biosimilars. In Letters to the Editor, Dr Carlo...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2012.0103-4.037

10.589 views

Read more โ†’

Abstracted Scientific Content

Published on 04 July 2012

Oncologists urged to embrace biosimilars to help control spiralling costs of cancer care

Oncologists urged to embrace biosimilars to help controlย spiralling costs of cancer care Oncologists have been urged to embrace biosimilar drug substitutionย to help control the spiralling costs of cancer care. However,...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2012.0102.022

7.767 views

Read more โ†’